Published in Osteoporos Int on February 12, 2008
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ (2010) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ (2009) 2.90
Low-energy distal radius fractures in middle-aged and elderly men and women--the burden of osteoporosis and fracture risk : A study of 1794 consecutive patients. Osteoporos Int (2009) 2.77
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Bone regeneration: current concepts and future directions. BMC Med (2011) 2.29
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab (2011) 1.88
A fractured service: the latest advice on osteoporosis. Br J Gen Pract (2009) 1.62
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int (2009) 1.53
Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res (2014) 1.52
Changing trends in the epidemiology of hip fracture in Spain. Osteoporos Int (2013) 1.52
Mortality after vertebral fracture in Korea: analysis of the National Claim Registry. Osteoporos Int (2011) 1.51
Use of pragmatic community-based interventions to enhance recruitment and adherence in a randomized trial of Tai Chi for women with osteopenia: insights from a qualitative substudy. Menopause (2014) 1.46
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int (2011) 1.43
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int (2016) 1.37
Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int (2009) 1.36
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
High resolution cortical bone thickness measurement from clinical CT data. Med Image Anal (2010) 1.33
Denosumab. Nat Rev Drug Discov (2010) 1.31
Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol (2012) 1.28
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int (2010) 1.18
The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study. Arthritis Res Ther (2010) 1.17
Validation of the Dutch guidelines for dual X-ray absorptiometry measurement. Br J Gen Pract (2009) 1.16
Association between atherosclerosis and osteoporosis, the role of vitamin D. Arch Med Sci (2011) 1.15
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int (2009) 1.12
Epidemiology of fragility fractures in Italy. Clin Cases Miner Bone Metab (2011) 1.10
Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int (2011) 1.08
Updated incidence rates of fragility fractures in Italy: extension study 2002-2008. Clin Cases Miner Bone Metab (2011) 1.08
Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporos Int (2010) 1.07
Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care (2012) 1.07
Antiepileptics and bone health. Ther Adv Musculoskelet Dis (2011) 1.06
Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep (2011) 1.06
Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone (2011) 1.06
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
The Relationships among Vitamin D Level, Balance, Muscle Strength, and Quality of Life in Postmenopausal Patients with Osteoporosis. J Phys Ther Sci (2014) 1.02
Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence. BMC Geriatr (2011) 1.00
Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int (2011) 1.00
Comparison between various fracture risk assessment tools. Osteoporos Int (2014) 1.00
Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World J Radiol (2013) 0.99
Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach. BMC Musculoskelet Disord (2008) 0.99
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Imaging the femoral cortex: thickness, density and mass from clinical CT. Med Image Anal (2012) 0.98
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int (2012) 0.96
Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int (2008) 0.96
Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study. Osteoporos Int (2013) 0.95
Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc (2012) 0.95
Induction of osteoporosis with its influence on osteoporotic determinants and their interrelationships in rats by DEXA. Med Sci Monit (2012) 0.95
The TARGET project in Tuscany: the first disease management model of a regional project for the prevention of hip re-fractures in the elderly. Clin Cases Miner Bone Metab (2010) 0.93
A comparison of three different guidelines for osteoporosis treatment in patients with rheumatoid arthritis in Korea. Korean J Intern Med (2010) 0.92
Updated fracture incidence rates for the Italian version of FRAX®. Osteoporos Int (2012) 0.92
High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int (2011) 0.92
Association between Sarcopenia, Bone Density, and Health-Related Quality of Life in Korean Men. Korean J Fam Med (2013) 0.92
Risk factors for nonvertebral fracture in obese older women. J Clin Endocrinol Metab (2011) 0.92
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol (2011) 0.91
Risk factors for osteoporosis are common in young and middle-aged patients with femoral neck fractures regardless of trauma mechanism. Acta Orthop (2013) 0.91
Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people. Arch Osteoporos (2009) 0.90
The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab (2013) 0.90
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int (2012) 0.90
Predicting Hip Fracture Type With Cortical Bone Mapping (CBM) in the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res (2015) 0.89
Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab (2013) 0.89
Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. BMC Musculoskelet Disord (2011) 0.89
Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications. Arch Osteoporos (2010) 0.89
The beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of action. Osteoporos Int (2012) 0.88
Undertreatment of osteoporosis in persons with dementia? A population-based study. Osteoporos Int (2011) 0.88
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther (2015) 0.88
FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord (2012) 0.87
Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? Calcif Tissue Int (2009) 0.87
Ten-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scores. Osteoporos Int (2009) 0.87
Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol (2009) 0.87
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
Clinical risk factors for osteoporosis are common among elderly people in Nuuk, Greenland. Int J Circumpolar Health (2013) 0.87
[Diagnostic approach to osteoporosis]. Wien Med Wochenschr (2009) 0.87
Ten years of hip fractures in Italy: For the first time a decreasing trend in elderly women. World J Orthop (2014) 0.86
Prediction of incident hip fracture by femoral neck bone mineral density and neck-shaft angle: a 5-year longitudinal study in post-menopausal females. Br J Radiol (2011) 0.86
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int (2009) 0.86
MENOPOST--calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int (2012) 0.86
Prevalence of vertebral fracture in oldest old nursing home residents. Osteoporos Int (2012) 0.86
Premenopausal women with a distal radial fracture have deteriorated trabecular bone density and morphology compared with controls without a fracture. J Bone Joint Surg Am (2013) 0.86
The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis. Osteoporos Int (2012) 0.86
A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int (2013) 0.86
Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU study. Osteoporos Int (2010) 0.86
Common polymorphisms rather than rare genetic variants of the Runx2 gene are associated with femoral neck BMD in Spanish women. J Bone Miner Metab (2010) 0.86
Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int (2009) 0.86
Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2012) 0.85
Effect of distributing an evidence-based guideline for prevention of osteoporosis on health education programs in municipal health centers: a randomized controlled trial. J Epidemiol (2011) 0.85
Pharmacological treatment of hip fractured patients in Italy: a simulation based on Tuscany regional database for the TARGET project. Clin Cases Miner Bone Metab (2010) 0.85
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med (1995) 13.01
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet (2007) 9.61
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet (1993) 9.34
Diagnosis of osteoporosis and assessment of fracture risk. Lancet (2002) 7.38
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Effect of Vitamin D on falls: a meta-analysis. JAMA (2004) 6.64
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med (1993) 6.08
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int (1994) 5.72
Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res (1997) 5.69
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med (2003) 5.45
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Assessment of fracture risk. Osteoporos Int (2004) 5.15
Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA (2001) 5.09
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health (2004) 4.98
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Prevention of falls and consequent injuries in elderly people. Lancet (2005) 4.84
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
Age and bone mass as predictors of fracture in a prospective study. J Clin Invest (1988) 4.46
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Concern Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA (2007) 3.63
Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ (2006) 3.53
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Treatment of postmenopausal osteoporosis. Lancet (2002) 3.37
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res (2002) 3.14
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int (2000) 2.99
A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res (2004) 2.92
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 2.75
Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev (2002) 2.65
The components of excess mortality after hip fracture. Bone (2003) 2.63
Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med (1992) 2.63
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res (1996) 2.47
Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ (2006) 2.35
Alcohol intake as a risk factor for fracture. Osteoporos Int (2004) 2.34
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int (2000) 2.14
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res (2004) 2.07
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab (2004) 1.96
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res (1997) 1.52
The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int (2005) 1.51
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res (2007) 1.45
Assessment of the risk of post-menopausal osteoporosis using clinical factors. Clin Endocrinol (Oxf) (1992) 1.44
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess (2005) 1.42
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res (2005) 1.39
Performance evaluation of a dual-energy x-ray bone densitometer. Calcif Tissue Int (1989) 1.38
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
Prevention of falls in the elderly. Bone (1996) 1.33
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Epidemiology of fractures in England and Wales. Bone (2001) 5.76
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet (2006) 4.95
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis (1992) 4.79
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
Dietary supplementation in elderly patients with fractured neck of the femur. Lancet (1990) 4.47
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
Bone density screening for osteoporosis. Lancet (1990) 3.87
Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. Lancet (1995) 3.82
Defining osteoarthritis of the hip for epidemiologic studies. Am J Epidemiol (1990) 3.77
Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Cohort profile: the Hertfordshire cohort study. Int J Epidemiol (2005) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Complete genomic sequence and analysis of the prion protein gene region from three mammalian species. Genome Res (1998) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Do we need to change the WHO definition of osteoporosis? Osteoporos Int (2000) 3.35
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. Lancet (2000) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
Pectin esterification is spatially regulated both within cell walls and between developing tissues of root apices. Planta (1990) 3.03
GP job satisfaction in 1987, 1990 and 1998: lessons for the future? Fam Pract (2000) 2.99
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
Maternal vitamin D status during pregnancy and child outcomes. Eur J Clin Nutr (2007) 2.94
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet (1996) 2.83
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int (2012) 2.81
Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) (2007) 2.81
Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1998) 2.81
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. BMJ (2000) 2.73
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
Osteoarthritis of the hip: an occupational disease in farmers. BMJ (1992) 2.69
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res (2000) 2.55
Occupational physical activities and osteoarthritis of the knee. Arthritis Rheum (2000) 2.54
Manual handling activities and risk of low back pain in nurses. Occup Environ Med (1995) 2.48
Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int (2012) 2.48
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
Use of statins and risk of fractures. JAMA (2001) 2.47
Prospective cohort study of predictors of incident low back pain in nurses. BMJ (1997) 2.46
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab (1992) 2.42
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage (2010) 2.39
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Trends in admissions for hip fracture in England and Wales, 1968-85. BMJ (1990) 2.35
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord (2001) 2.30
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab (1991) 2.27
How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum (2008) 2.27
Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology (2012) 2.25
Bone strength and its determinants. Osteoporos Int (2003) 2.25
Vertebral fractures predict subsequent fractures. Osteoporos Int (1999) 2.24
Dietary calcium, physical activity, and risk of hip fracture: a prospective study. BMJ (1989) 2.24
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res (2000) 2.24
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study. Rheumatology (Oxford) (2005) 2.23
Acetabular dysplasia and hip osteoarthritis in Britain and Japan. Br J Rheumatol (1998) 2.22
Bacterial arthritis in an English health district: a 10 year review. Ann Rheum Dis (1986) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med (2008) 2.19
The role of collagen in bone strength. Osteoporos Int (2005) 2.19
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis (2001) 2.18
Vitamin D and skeletal health in infancy and childhood. Osteoporos Int (2014) 2.16
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) (2000) 2.13
The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) (2005) 2.11
Physical activity at 36 years: patterns and childhood predictors in a longitudinal study. J Epidemiol Community Health (1992) 2.11
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev (2006) 2.08
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Use of oral corticosteroids in the United Kingdom. QJM (2000) 1.95
Are rates of ageing determined in utero? Age Ageing (1998) 1.95
Will elderly rest home residents wear hip protectors? Age Ageing (1998) 1.95
Muscle strength, activity, housing and the risk of falls in elderly people. Age Ageing (1989) 1.94